John Richert

Learn More
OBJECTIVE In this cohort of individuals with and without multiple sclerosis (MS), we illustrate some of the novel approaches that smartphones provide to monitor patients with chronic neurologic disorders in their natural setting. METHODS Thirty-eight participant pairs (MS and cohabitant) aged 18-55 years participated in the study. Each participant(More)
Objective: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on MRI lesion activity and load, atrophy, and magnetization transfer ratio (MTR) measures from the Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) study. Methods: CONFIRM was a 2-year, placebo-controlled(More)
Background: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuropro-tective effects. In clinical trials, DMF was associated with reduced white blood cell and absolute lymphocyte counts. Current US prescribing(More)
Objective: In this cohort of individuals with and without multiple sclerosis (MS), we illustrate some of the novel approaches that smartphones provide to monitor patients with chronic neurologic disorders in their natural setting. Methods: Thirty-eight participant pairs (MS and cohabitant) aged 18–55 years participated in the study. Each participant(More)
ii ACKNOWLEDGEMENTS I must thank Dr. Kip Matthews for inspiring a passion for medical imaging. I will always be grateful for his skillful guidance in introducing me to the world of research. His boundless patience, understanding and willingness to help at all times will always stay with me. I am indebted. I also thank the other members of my thesis(More)
  • 1